HomeBUSINESS
BUSINESS

JCR’s BBB-Penetrating Hunter Syndrome Drug Delivers Positive PI/II Data; PII/III Study to Start Next Year
(Dec.15.2017)

JCR Pharmaceuticals announced on December 13 the topline results of a PI/II study of its Hunter’s syndrome treatment JR-141. No safety-related problems were observed, and the reduction of heparan sulfate in cerebrospinal fluid, a marker of CNS symptoms, was confirmed in all patients. Based on the results, JCR plans to initiate a PII/III study next year ...
(LOG IN FOR FULL STORY)

News Calendar